Wall Street Analysts Downgrade EyePoint Pharmaceuticals Following Clinical Trial Results

EyePoint Pharmaceuticals (EYPT) faced multiple downgrades from Wall Street analysts after its Phase 3 LUCIA trial failed to meet its primary endpoint. JPMorgan downgraded the stock to Underweight from Neutral, Mizuho Securities lowered its rating to Hold with a reduced price target of $0.50, and Guggenheim changed its rating from Buy to Neutral. These downgrades indicate a negative shift in analyst sentiment regarding the company's future clinical prospects and valuation.